文献速递血管炎其他结缔组织病

COVID-19相关儿童血管炎:系统综述及发病机制详细分析

COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis.
PubMed 文献 · Semin Arthritis Rheum · 2022-06-09

该系统综述检索截至2022年1月1日的文献,纳入25篇文献共36例COVID-19相关儿童血管炎患者(中位年龄13岁,男女比2.3),最常见表型为IgA血管炎(9例),其次为冻疮样皮损(7例)和ANCA相关性血管炎(5例);皮肤(58.3%)和肾脏(30.5%)受累最常见,28例中23例达到缓解,5例死亡。

要点

  • COVID-19相关儿童血管炎极罕见,最常见表型为IgA血管炎,其次为冻疮样皮损和ANCA相关性血管炎。
  • 皮肤(58.3%)和肾脏(30.5%)受累是最常见的临床表现。
  • 28例中23例达到缓解,5例死亡(4例中枢神经系统血管炎,1例ANCA相关性血管炎)。

核心结论

  • COVID-19相关儿童血管炎极罕见,认识该罕见疾病对早期诊断和治疗很重要。
  • COVID-19相关儿童血管炎各亚型的临床特征与无COVID-19相关的儿童血管炎相似。
  • COVID-19是血管炎的原因还是仅为触发因素尚不清楚。

研究设计与样本

  • 通过Pubmed/MEDLINE和Scopus对截至2022年1月1日的英文文献进行系统综述。
  • 纳入标准为:血管炎起病年龄<18岁、有SARS-CoV-2暴露证据、有血管炎诊断证据(影像学、组织病理学证据或符合特定诊断/分类标准)。
  • 排除与儿童多系统炎症综合征(MIS-C)相关的川崎病样血管炎患者。
  • 最终纳入25篇文献,共描述36例COVID-19相关儿童血管炎患者(中位年龄13岁;男女比2.3)。

主要发现

  • 最常见表型为IgA血管炎(n=9),其次为冻疮样皮损(n=7)和ANCA相关性血管炎(AAV)(n=5)。
  • 皮肤(58.3%)和肾脏(30.5%)受累是最常见的血管炎表现。
  • 多数患者接受糖皮质激素治疗(40%),最常用的免疫抑制药物为利妥昔单抗(14.2%)和环磷酰胺(11.4%)。
  • 28例患者中23例达到缓解。
  • 5例患者死亡,其中4例为中枢神经系统血管炎、1例为ANCA相关性血管炎。

关键数值与推荐

  • 纳入标准:血管炎起病年龄<18岁、有SARS-CoV-2暴露证据、有血管炎诊断证据(影像学、组织病理学证据或符合特定诊断/分类标准)。
  • 排除与儿童多系统炎症综合征(MIS-C)相关的川崎病样血管炎患者。
  • 最常见表型为IgA血管炎(n=9),其次为冻疮样皮损(n=7)和ANCA相关性血管炎(n=5)。
  • 皮肤受累占58.3%,肾脏受累占30.5%。
  • 糖皮质激素使用率40%,利妥昔单抗14.2%,环磷酰胺11.4%;28例中23例达到缓解,5例死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出COVID-19是血管炎的原因还是仅为触发因素尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, has opened a new era in the practice of pediatric rheumatology since it has been associated with inflammatory complications such as vasculitis and arthritis. In this review, we aimed to present a detailed analysis of COVID-19 associated pediatric vasculitis. METHODS: A systematic review of the English literature was performed through Pubmed/MEDLINE and Scopus up to January 1st, 2022. Articles including data about the patients with 1) onset of vasculitis <18 years of age, 2) evidence of SARS-CoV-2 exposure, 3) evidence of vasculitis diagnosis (imaging, histopathologic evidences or fulfilling the specific diagnostic/classification criteria) were included in the final analysis. Patients with Kawasaki disease-like vasculitis associated with multisystem inflammatory syndrome in children (MIS-C) were excluded. RESULTS: A total of 25 articles describing 36 patients with COVID-19 associated pediatric vasculitis (median age 13 years; M/F: 2.3) were included. The most frequent phenotype was IgA vasculitis (n=9) followed by chilblains (n=7) and ANCA associated vasculitis (AAV) (n=5). Skin (58.3%) and renal (30.5%) involvements were the most common manifestations of vasculitis. The majority of patients received corticosteroids (40%), while rituximab (14.2%) and cyclophosphamide (11.4%) were the most frequently used immunosuppressive drugs. Remission was achieved in 23 of 28 patients. Five patients (4 with central nervous system vasculitis; 1 with AAV) died. CONCLUSION: Although COVID-19 associated pediatric vasculitis is very rare, awareness of this rare entity is important to secure earlier diagnosis and treatment. The clinical features of COVID-19 associated pediatric vasculitis subtypes look similar to those in pediatric vasculitis not associated with COVID-19. Whether COVID-19 is the reason of the vasculitis or only the trigger remains unknown.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Batu ED, Sener S, Ozen S, et al. COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis. Semin Arthritis Rheum. 2022. PMID: 35709649. doi:10.1016/j.semarthrit.2022.152047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。